1-15 of 15
William C. Zamboni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models

Gina Song, David B. Darr, Charlene M. Santos, Mark Ross, Alain Valdivia, Jamie L. Jordan, Bentley R. Midkiff, Stephanie Cohen, Nana Nikolaishvili-Feinberg, C. Ryan Miller, Teresa K. Tarrant, Arlin B. Rogers, Andrew C. Dudley, Charles M. Perou, William C. Zamboni
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 6083–6095.
https://doi.org/10.1158/1078-0432.CCR-14-0493
Published: 30 November 2014
View article titled, Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Open the PDF for Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models in another window
Includes: Supplementary data
Journal Articles

A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents

Whitney P. Caron, Katherine P. Morgan, Beth A. Zamboni, William C. Zamboni
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3309–3315.
https://doi.org/10.1158/1078-0432.CCR-12-3649
Published: 13 June 2013
View article titled, A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents
Open the PDF for A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents in another window
Journal Articles

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

Patrick J. Roberts, Jerry E. Usary, David B. Darr, Patrick M. Dillon, Adam D. Pfefferle, Martin C. Whittle, James S. Duncan, Soren M. Johnson, Austin J. Combest, Jian Jin, William C. Zamboni, Gary L. Johnson, Charles M. Perou, Norman E. Sharpless
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5290–5303.
https://doi.org/10.1158/1078-0432.CCR-12-0563
Published: 30 September 2012
View article titled, Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Open the PDF for Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models in another window
Includes: Supplementary data
Journal Articles

Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance

William C. Zamboni, Vladimir Torchilin, Anil K. Patri, Jeff Hrkach, Stephen Stern, Robert Lee, Andre Nel, Nicholas J. Panaro, Piotr Grodzinski
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3229–3241.
https://doi.org/10.1158/1078-0432.CCR-11-2938
Published: 14 June 2012
View article titled, Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Open the PDF for Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance in another window
Journal Articles

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

Mark D. Walsh, Suzan K. Hanna, Jeremy Sen, Sumit Rawal, Carolina B. Cabral, Alex V. Yurkovetskiy, Robert J. Fram, Timothy B. Lowinger, William C. Zamboni
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2591–2602.
https://doi.org/10.1158/1078-0432.CCR-11-1554
Published: 30 April 2012
View article titled, Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts
Open the PDF for Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts in another window
Journal Articles

Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies

William C. Zamboni, Suresh Ramalingam, David M. Friedland, Robert P. Edwards, Ronald G. Stoller, Sandra Strychor, Lauren Maruca, Beth A. Zamboni, Chandra P. Belani, Ramesh K. Ramanathan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1466–1472.
https://doi.org/10.1158/1078-0432.CCR-08-1405
Published: 19 February 2009
View article titled, Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies in another window
Journal Articles

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts

William C. Zamboni, Sandra Strychor, Erin Joseph, Dustin R. Walsh, Beth A. Zamboni, Robert A. Parise, Margaret E. Tonda, Ning Y. Yu, Charles Engbers, Julie L. Eiseman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7217–7223.
https://doi.org/10.1158/1078-0432.CCR-07-1035
Published: 03 December 2007
View article titled, Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts
Open the PDF for Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts in another window
Journal Articles

Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents

William C. Zamboni
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8230–8234.
https://doi.org/10.1158/1078-0432.CCR-05-1895
Published: 01 December 2005
View article titled, Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
Open the PDF for Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents in another window
Journal Articles

Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors

Marwan G. Fakih, Patrick J. Creaven, Nithya Ramnath, Donald Trump, Milind Javle, Sandra Strychor, Trisha V.W. Repinski, Beth A. Zamboni, James K. Schwarz, Renee A. French, William C. Zamboni
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5942–5949.
https://doi.org/10.1158/1078-0432.CCR-05-0116
Published: 22 August 2005
View article titled, Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors in another window
Journal Articles

Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts

William C. Zamboni, Laura L. Jung, Merrill J. Egorin, Deborah R. Hamburger, Erin Joseph, Ruzhi Jin, Sandra Strychor, Ramesh K. Ramanathan, Julie L. Eiseman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4867–4874.
https://doi.org/10.1158/1078-0432.CCR-05-0144
Published: 06 July 2005
View article titled, Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts
Open the PDF for Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts in another window
Journal Articles

Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors

William C. Zamboni, Laura L. Jung, Merrill J. Egorin, Douglas M. Potter, David M. Friedland, Chandra P. Belani, Sanjiv S. Agarwala, Michael M. W. Wong, Marwan Fakih, Donald L. Trump, Ruzhi Jin, Sandra Strychor, Michael Vozniak, Monica Troetschel, Ramesh K. Ramanathan
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5058–5064.
https://doi.org/10.1158/1078-0432.CCR-03-0288
Published: 05 August 2004
View article titled, Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors in another window
Journal Articles

A Pilot Study of Protracted Topotecan Dosing Using a Pharmacokinetically Guided Dosing Approach in Children with Solid Tumors

Victor M. Santana, William C. Zamboni, Mark N. Kirstein, Ming Tan, Tiebin Liu, Amar Gajjar, Peter J. Houghton, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 633–640.
Published: 01 February 2003
View article titled, A Pilot Study of Protracted Topotecan Dosing Using a Pharmacokinetically Guided Dosing Approach in Children with Solid Tumors
Open the PDF for A Pilot Study of Protracted Topotecan Dosing Using a Pharmacokinetically Guided Dosing Approach in Children with Solid Tumors in another window
Journal Articles

Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin

William C. Zamboni, Anne C. Gervais, Merrill J. Egorin, Jan H. M. Schellens, Deborah R. Hamburger, Brian J. Delauter, Amy Grim, Eleanor G. Zuhowski, Erin Joseph, Dick Pluim, Douglas M. Potter, Julie L. Eiseman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2992–2999.
Published: 01 September 2002
View article titled, Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin
Open the PDF for Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin in another window
Journal Articles

Pharmacodynamic Model of Topotecan-induced Time Course of Neutropenia

William C. Zamboni, David Z. D’Argenio, Clinton F. Stewart, Tom MacVittie, Brian J. Delauter, Ann M. Farese, Douglas M. Potter, Nacole M. Kubat, David Tubergen, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2301–2308.
Published: 01 August 2001
View article titled, Pharmacodynamic Model of Topotecan-induced Time Course of Neutropenia
Open the PDF for Pharmacodynamic Model of Topotecan-induced Time Course of Neutropenia in another window
Journal Articles

Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan

Margaret K. Ma, William C. Zamboni, Kristine M. Radomski, Wayne L. Furman, Victor M. Santana, Peter J. Houghton, Suzan K. Hanna, Audrey K. Smith, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (3): 813–819.
Published: 01 March 2000
View article titled, Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan
Open the PDF for Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan in another window